| Q28384242 | 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal |
| Q35176131 | A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor |
| Q37285301 | Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells |
| Q80468799 | DNA methylation changes in multiple myeloma |
| Q37314994 | Epigenetic cross-talk between DNA methylation and histone modifications in human cancers |
| Q24812104 | Epigenetics of cervical cancer. An overview and therapeutic perspectives |
| Q43251030 | Hydralazine target: from blood vessels to the epigenome |
| Q28477824 | Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment |
| Q36338022 | Methylation inhibitor therapy in the treatment of myelodysplastic syndrome |
| Q38544350 | Oncogenic cancer/testis antigens: prime candidates for immunotherapy. |
| Q36338026 | Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. |
| Q42081115 | Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells |
| Q38736229 | Peperomin E reactivates silenced tumor suppressor genes in lung cancer cells by inhibition of DNA methyltransferase |
| Q39780644 | Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition |
| Q36459959 | Role of DNA methyltransferases in regulation of human ribosomal RNA gene transcription |
| Q28741003 | Role of protein tyrosine phosphatases in cancer |
| Q33847891 | Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target |
| Q37022672 | Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. |
| Q37699106 | Understanding oral cancer in the genome era. |